DUBLIN--(BUSINESS WIRE)--The "Investigation Report on China's Insulin Glargine Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

According to the market research, the sales value of Insulin Glargine has shown an upward trend from 2016 to 2020 in China, reaching CNY960.49 million in 2020. Sales growth in 2020 has slowed down compared to previous years.

The main reason is that the COVID-19 epidemic has impacted the hospital's overall diagnosis and treatment business. The CAGR of the sales value of Insulin Glargine in the Chinese market is 5.45% from 2016 to 2020.

Insulin Glargine is a long-acting human insulin analog that can control the patient's blood sugar more effectively and steadily. It is often used to treat type 1 and type 2 diabetes. Its original research manufacturer is Sanofi, and its trade name is Lantus, which came to the Chinese market in 2004. In 2020, in addition to the original research company, other manufacturers in the Chinese Insulin Glargine market are Gan&Lee Pharmaceuticals Co., Ltd. and Zhuhai United Laboratories Co., Ltd.

The analyst predicts that from 2021 to 2025, the sales of Insulin Glargine in China will have a recovery growth with the improvement of the epidemic and the normal operation of the hospital's overall diagnosis and treatment business. In addition, its sales will also increase due to market expansion.

The number of diabetic patients in China has ranked the first in the world, and there is a great demand for diabetes treatment drugs. Insulin Glargine belongs to the third generation of insulin. Compared with other types of insulin, third-generation insulin has greater advantages in terms of onset time, peak performance, and duration of action, indicating that the Insulin Glargine market has room for growth in China.

In addition, the key patent of Insulin Glargine expired in 2015, and more generic drugs will appear in the Insulin Glargine market in the future. Therefore, the price of Insulin Glargine is expected to continue to fall, driving sales volume to increase sales.

Topics Covered:

• The impact of COVID-19 on China's Insulin Glargine market
• Sales value of China's Insulin Glargine 2016-2020
• Competitive landscape of China's Insulin Glargine market
• Prices of Insulin Glargine in China
• Prices of Insulin Glargine in China by regions and manufacturers
• Analysis of factors affecting the development of China's Insulin Glargine market
• Prospect of China's Insulin Glargine market from 2021 to 2025

Key Topics Covered:

1 Relevant Concepts of Insulin Glargine

1.1 Indications for Insulin Glargine

1.2 Development of Insulin Glargine in China

1.3 Governmental Approval of Insulin Glargine in China

1.4 The Impact of COVID-19 on Insulin Glargine Sales in China

2 Sales of Insulin Glargine in China, 2016-2020

2.1 Sales Value of Insulin Glargine

2.1.1 Overall Sales Value

2.1.2 Sales Value by Region

2.2 Sales Volume of Insulin Glargine

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 Sales of Insulin Glargine by Dosage Form in China, 2016-2020

2.3.1 Injection

2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Insulin Glargine Manufacturers in China, 2016-2020

3.1 Analysis of Market Share of Major Insulin Glargine Manufacturers

3.1.1 Investigation on Market Share by Sales Value

3.1.2 Investigation on Market Share by Sales Volume

3.2 Sanofi-Aventis Deutschland GmbH Germany

3.2.1 Enterprise Profile

3.2.2 Sales of LANTUS &TOUJEO (Sanofi-Aventis Deutschland GmbH Germany's Insulin Glargine) in China

3.3 Gan&Lee Pharmaceuticals Co., Ltd.

3.3.1 Enterprise Profile

3.3.2 Sales of BASALIN (Gan&Lee Pharmaceuticals Co., Ltd.'s Insulin Glargine) in China

3.4 Zhuhai United Laboratories Co., Ltd.

3.4.1 Enterprise Profile

3.4.2 Sales of USLEN (Zhuhai United Laboratories Co., Ltd.'s Insulin Glargine) in China

4 Prices of Insulin Glargine for Different Manufacturers in China, 2020-2021

4.1 Sanofi-Aventis Deutschland GmbH Germany (LANTUS &TOUJEO)

4.2 Gan&Lee Pharmaceuticals Co., Ltd. (BASALIN)

4.3 Zhuhai United Laboratories Co., Ltd. (USLEN)

5 Prospect of Chinese Insulin Glargine Market, 2021-2025

5.1 Influential Factors of Chinese Insulin Glargine Market Development

5.1.1 The Impact of COVID-19 on Chinese Insulin Glargine Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

For more information about this report visit https://www.researchandmarkets.com/r/rgchit

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900